This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08553/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB08553/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08553/identifier/pubchem-substance/
n13http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB08553/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08553/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08553
rdf:type
n3:Drug
n3:description
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.
n3:group
experimental
owl:sameAs
n8:DB08553 n13:DB08553
dcterms:title
(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
adms:identifier
n6:DB08553 n9:SM5 n10:9828390 n11:11653652 n12:99445024
n3:IUPAC-Name
n4:271B6352-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6358-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6357-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6354-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6355-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6356-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6350-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6351-363D-11E5-9242-09173F13E4C5 n4:271B634E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B634F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B635E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B635F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6359-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B635A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B635C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B635B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B635D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6364-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6366-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6367-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6363-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6362-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6365-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6353-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6360-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6361-363D-11E5-9242-09173F13E4C5